Difluprednate (BioDeep_00000009377)

 

Secondary id: BioDeep_00000858451

human metabolite blood metabolite Chemicals and Drugs Volatile Flavor Compounds


代谢物信息卡片


(1R,2S,8S,10S,11S,14R,15S,17S)-14-[2-(acetyloxy)acetyl]-1,8-difluoro-17-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-14-yl butanoate

化学式: C27H34F2O7 (508.22724780000004)
中文名称: 二氟孕甾丁酯
谱图信息: 最多检出来源 Homo sapiens(blood) 11.11%

分子结构信息

SMILES: CCCC(=O)OC1(C(=O)COC(C)=O)CCC2C3CC(F)C4=CC(=O)C=CC4(C)C3(F)C(O)CC21C
InChI: InChI=1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1

描述信息

Difluprednate is only found in individuals that have used or taken this drug. It is a topical corticosteroid indicated for the treatment of inflammation and pain associated with ocular surgery. It was approved by the US Food and Drug Administration (FDA) on June 24, 2008. Corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins (lipocortins). It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
D - Dermatologicals > D07 - Corticosteroids, dermatological preparations > D07A - Corticosteroids, plain > D07AC - Corticosteroids, potent (group iii)
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D005938 - Glucocorticoids
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone
C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid
Same as: D01266
Difluprednate is a topical corticosteroid, which is thought to act by the induction of phospholipase A2 inhibitory proteins (lipocortins). Difluprednate is used for the symptomatic treatment of inflammation and pain associated with ocular surgery.

同义名列表

15 个代谢物同义名

(1R,2S,8S,10S,11S,14R,15S,17S)-14-[2-(acetyloxy)acetyl]-1,8-difluoro-17-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-14-yl butanoate; (6alpha,11beta)-21-(Acetyloxy)-6,9-difluoro-11-hydroxy-17-(1-oxobutoxy)pregna-1,4-diene-3,20-dione; (6Α,11β)-21-(acetyloxy)-6,9-difluoro-11-hydroxy-17-(1-oxobutoxy)pregna-1,4-diene-3,20-dione; 6alpha,9alpha-Difluoroprednisolone 21-acetate 17-butyrate; 6alpha,9-Difluoroprednisolone 21-acetate 17-butyrate; 6Α,9α-difluoroprednisolone 21-acetate 17-butyrate; 6Α,9-difluoroprednisolone 21-acetate 17-butyrate; Difluoroprednisolone butyrate acetate; Difluprednic acid; Difluprednate; SCHEMBL4581; Epitopic; Durezol; DFBA; Difluprednate



数据库引用编号

16 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • B Kaviarasi, Naveen Rajana, Yeruva Sri Pooja, A N Rajalakshmi, Shashi Bala Singh, Neelesh Kumar Mehra. Investigating the effectiveness of Difluprednate-Loaded core-shell lipid-polymeric hybrid nanoparticles for ocular delivery. International journal of pharmaceutics. 2023 May; 640(?):123006. doi: 10.1016/j.ijpharm.2023.123006. [PMID: 37137420]
  • Zhi Wen, Jingfu Zhang, Guido Powell, Imane Chafi, David L Buckeridge, Yue Li. EpiTopics: A dynamic machine learning model to predict and inform non-pharmacological public health interventions from global news reports. STAR protocols. 2022 06; 3(2):101463. doi: 10.1016/j.xpro.2022.101463. [PMID: 35712009]
  • Estelle Geffard, Léo Boussamet, Alexandre Walencik, Florent Delbos, Sophie Limou, Pierre-Antoine Gourraud, Nicolas Vince. HLA-EPI: A new EPIsode in exploring donor/recipient epitopic compatibilities. HLA. 2022 02; 99(2):79-92. doi: 10.1111/tan.14505. [PMID: 34862850]
  • Katelin Quantz, Amanda L Anderson, Christine D Harman, Erica L Noland, Jacquelyn M Del Valle, Laurence M Occelli, Jessica B Burn, Simon M Petersen-Jones, Daniel K Langlois, Chris G Pirie, Annette D Petersen, András M Komáromy. Localized alopecia and suppression of hypothalamic-pituitary-adrenal (HPA) axis in dogs following treatment with difluprednate 0.05\% ophthalmic emulsion (Durezol®). BMC veterinary research. 2021 Dec; 17(1):366. doi: 10.1186/s12917-021-03072-9. [PMID: 34847929]
  • Parvin Moghaddam, Azadeh Zahmatkesh, Masoumeh Bagheri, Homayoon Mahravani. Are Epitopic Sites of 3AB and 3D Nonstructural Proteins Sufficient for Detection of Foot and Mouth Disease?. Viral immunology. 2021 03; 34(2):79-85. doi: 10.1089/vim.2020.0144. [PMID: 33296262]
  • Anubhab Laha, Rajib Bandopadhyay, Anindya Sundar Panja. Structural Phylogeny of Different Allergens May Reveal Common Epitopic Footprint. Protein and peptide letters. 2021; 28(10):1099-1107. doi: 10.2174/0929866528666210622145710. [PMID: 34161203]
  • Anton M Kolomeyer, Shyam Kodati. Lamotrigine-induced tubulointerstitial nephritis and uveitis-atypical Cogan syndrome. European journal of ophthalmology. 2015 Dec; 26(1):e14-6. doi: 10.5301/ejo.5000674. [PMID: 26350991]
  • Tetsuya Tajika, Mitsunori Waki, Masakatsu Tsuzuki, Tetsuo Kida, Hideyuki Sakaki. Pharmacokinetic features of difluprednate ophthalmic emulsion in rabbits as determined by glucocorticoid receptor-binding bioassay. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2011 Feb; 27(1):29-34. doi: 10.1089/jop.2010.0106. [PMID: 21182429]
  • Tetsuya Tajika, Akiharu Isowaki, Hideyuki Sakaki. Ocular distribution of difluprednate ophthalmic emulsion 0.05\% in rabbits. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2011 Feb; 27(1):43-9. doi: 10.1089/jop.2010.0093. [PMID: 21118027]
  • Masazumi Yamaguchi, Shin-ichi Yasueda, Akiharu Isowaki, Makiko Yamamoto, Masako Kimura, Katsuhiro Inada, Akira Ohtori. Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. International journal of pharmaceutics. 2005 Sep; 301(1-2):121-8. doi: 10.1016/j.ijpharm.2005.05.036. [PMID: 16023810]
  • K D Morton, L D Van de Kar, M S Brownfield, C L Bethea. Neuronal cell bodies in the hypothalamic paraventricular nucleus mediate stress-induced renin and corticosterone secretion. Neuroendocrinology. 1989 Jul; 50(1):73-80. doi: 10.1159/000125204. [PMID: 2666872]
  • T Higuchi, Y Kurashima, H Miida, M Higuchi. [Chronic toxicity study on difluprednate in dogs]. The Journal of toxicological sciences. 1985 May; 10(2):107-34. doi: 10.2131/jts.10.107. [PMID: 4032501]
  • Y Aizawa, H Kogo, K Yamada, N Inazu, T Matsudaira. [Effect of difluprednate on adrenocortical and gonadal function]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 1984 Dec; 84(6):553-61. doi: 10.1254/fpj.84.553. [PMID: 6519585]